Retour
Fourchette du Jour
116,74 €
120,12 €
Fourchette 52 Semaines
73,31 €
125,14 €
Volume
6 937 576
Moyenne 50J / 200J
115,65 €
/
94,64 €
Clôture Précédente
116,37 €
Quick Summary
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Healthcare (627 pairs)
| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | 16,2 | 0,3 |
| P/B | 5,6 | 3,0 |
| ROE % | 36,9 | 3,7 |
| Net Margin % | 28,1 | 3,8 |
| Rev Growth 5Y % | 7,5 | 10,0 |
| D/E | 1,0 | 0,2 |
Objectif de Cours des Analystes
Hold
128,54 €
+7.7%
Low: 100,00 €
High: 150,00 €
P/E Prévisionnel
23,30
BPA Prévisionnel
5,12 €
Croissance BPA (est.)
+0,0%
CA Est.
66,76B
Estimations de Bénéfices
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| FY2030 |
10,16 €
9,87 € – 10,37 €
|
74,13B | 5 |
| FY2029 |
10,36 €
10,07 € – 10,58 €
|
74,56B | 2 |
| FY2028 |
10,77 €
8,85 € – 13,13 €
|
74,79B | 7 |
No quarterly estimates available
Earnings Surprises
Last 8 quarters
| Quarter | Est. EPS | Actual EPS | Surprise |
|---|---|---|---|
| 2026-02-03 | 2,01 € | 2,04 € | +1,5% |
| 2025-10-30 | 2,36 € | 2,58 € | +9,3% |
| 2025-07-29 | 2,03 € | 2,13 € | +4,9% |
| 2025-04-24 | 2,13 € | 2,22 € | +4,2% |
| 2025-02-04 | 1,85 € | 1,72 € | -7,0% |
| 2024-10-31 | 1,50 € | 1,57 € | +4,7% |
| 2024-07-30 | 2,15 € | 2,28 € | +6,0% |
| 2024-04-25 | 1,88 € | 2,07 € | +10,1% |
Insider Trading Activity
Buy ratio (90d)
0.0%
15 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 6, 2026 |
DeLuca Richard R.
EVP&Pres, Merck Animal Heallth
|
sell | 37 685 | 120,92 € | 4 557 024,71 € |
| Feb 6, 2026 |
Oosthuizen Johannes Jacobus
President, U.S. Market
|
sell | 15 000 | 121,87 € | 1 827 991,50 € |
| Jan 26, 2026 |
Litchfield Caroline
EVP & CFO
|
grant | 15 852 | 107,40 € | 1 702 504,80 € |
| Jan 26, 2026 |
Guindo Chirfi
Chief Marketing Officer
|
grant | 9 865 | 107,40 € | 1 059 501,00 € |
| Jan 26, 2026 |
Li Dean Y
Executive VP & President, MRL
|
grant | 20 469 | 107,40 € | 2 198 370,60 € |
| Jan 26, 2026 |
Davis Robert M
Chairman, CEO & President
|
grant | 47 434 | 107,40 € | 5 094 411,60 € |
| Dec 31, 2025 |
Seidman Christine E
Director
|
grant | 77 | 105,26 € | 8 105,02 € |
| Nov 10, 2025 |
Downing Cristal N
Chief Comm. & Public Afrs Ofcr
|
sell | 7 085 | 87,00 € | 616 395,00 € |
| Sep 30, 2025 |
Coe Mary Ellen
Director
|
grant | 357 | 83,93 € | 29 963,01 € |
| Sep 30, 2025 |
Seidman Christine E
Director
|
grant | 97 | 83,93 € | 8 141,21 € |
| Jun 30, 2025 |
GLOCER THOMAS H
Director
|
grant | 616 | 79,16 € | 48 762,56 € |
| Jun 30, 2025 |
Seidman Christine E
Director
|
grant | 103 | 79,16 € | 8 153,48 € |
| May 30, 2025 |
Craig Pamela J.
Director
|
grant | 2 863 | 76,84 € | 219 992,92 € |
| May 30, 2025 |
Seidman Christine E
Director
|
grant | 2 863 | 76,84 € | 219 992,92 € |
| Mar 31, 2025 |
Seidman Christine E
Director
|
grant | 91 | 89,76 € | 8 168,16 € |
Dividend History
7 yr streakYield
0,03%
Payout Ratio
0,45%
Growth (3Y)
5,42%
Growth (5Y)
5,75%
| Ex-Date | Payment Date | Amount | Yield |
|---|---|---|---|
| Mar 16, 2026 | Apr 07, 2026 | 0,85 € | 2,88% |
| Dec 15, 2025 | Jan 08, 2026 | 0,85 € | 3,27% |
| Sep 15, 2025 | Oct 07, 2025 | 0,81 € | 4,00% |
| Jun 16, 2025 | Jul 08, 2025 | 0,81 € | 3,95% |
| Mar 17, 2025 | Apr 07, 2025 | 0,81 € | 3,33% |
| Dec 16, 2024 | Jan 08, 2025 | 0,81 € | 3,12% |
| Sep 16, 2024 | Oct 07, 2024 | 0,77 € | 2,61% |
| Jun 17, 2024 | Jul 08, 2024 | 0,77 € | 2,38% |
| Mar 14, 2024 | Apr 05, 2024 | 0,77 € | 2,49% |
| Dec 14, 2023 | Jan 08, 2024 | 0,77 € | 2,80% |
| Sep 14, 2023 | Oct 06, 2023 | 0,73 € | 2,70% |
| Jun 14, 2023 | Jul 10, 2023 | 0,73 € | 2,65% |
| Mar 14, 2023 | Apr 10, 2023 | 0,73 € | 2,65% |
| Dec 14, 2022 | Jan 09, 2023 | 0,73 € | 2,51% |
| Sep 14, 2022 | Oct 07, 2022 | 0,69 € | 3,17% |
| Jun 14, 2022 | Jul 08, 2022 | 0,69 € | 3,22% |
| Mar 14, 2022 | Apr 07, 2022 | 0,69 € | 3,45% |
| Dec 14, 2021 | Jan 07, 2022 | 0,69 € | 3,54% |
| Sep 14, 2021 | Oct 07, 2021 | 0,65 € | 3,52% |
| Jun 14, 2021 | Jul 07, 2021 | 0,65 € | 3,28% |
Points Clés
Revenue grew 7,49% annually over 5 years — modest growth
ROE of 36,91% indicates high profitability
Net margin of 28,08% shows strong profitability
Generating 12,36B in free cash flow
Revenue growth is decelerating — 1Y growth trails 5Y average by 6,18%
Capital efficient — spends only 6,33% of revenue on capex
Croissance
Revenue Growth (5Y)
7,49%
Revenue (1Y)1,31%
Earnings (1Y)6,64%
FCF Growth (3Y)16,27%
Qualité
Return on Equity
36,91%
ROIC19,47%
Net Margin28,08%
Op. Margin41,19%
Sécurité
Debt / Equity
0,96
Current Ratio1,54
Interest Coverage0,00
Valorisation
P/E Ratio
16,17
Forward P/E22,57
P/B Ratio5,61
EV/EBITDA12,36
Dividend Yield0,03%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 1,31% | Revenue Growth (3Y) | 3,99% |
| Earnings Growth (1Y) | 6,64% | Earnings Growth (3Y) | 607,18% |
| Revenue Growth (5Y) | 7,49% | Earnings Growth (5Y) | 8,75% |
| Profitability | |||
| Revenue (TTM) | 65,01B | Net Income (TTM) | 18,25B |
| ROE | 36,91% | ROA | 13,34% |
| Gross Margin | 81,50% | Operating Margin | 41,19% |
| Net Margin | 28,08% | Free Cash Flow (TTM) | 12,36B |
| ROIC | 19,47% | FCF Growth (3Y) | 16,27% |
| Safety | |||
| Debt / Equity | 0,96 | Current Ratio | 1,54 |
| Interest Coverage | 0,00 | ||
| Dividends | |||
| Dividend Yield | 0,03% | Payout Ratio | 0,45% |
| Dividend Growth (3Y) | 5,42% | Dividend Growth (5Y) | 5,75% |
| Consecutive Div Years | 7 yrs | ||
| Valuation | |||
| P/E Ratio | 16,17 | Forward P/E | 22,57 |
| P/B Ratio | 5,61 | P/S Ratio | 4,54 |
| PEG Ratio | 1,88 | Forward PEG | N/A |
| EV/EBITDA | 12,36 | Fwd EV/EBITDA | 11,51 |
| Forward P/S | 4,42 | Fwd Earnings Yield | 4,43% |
| FCF Yield | 4,19% | ||
| Market Cap | 295,13B | Enterprise Value | 331,10B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 65,01B | 64,17B | 60,12B | 59,28B | 48,70B |
| Net Income | 18,25B | 17,12B | 365,00M | 14,52B | 13,05B |
| EPS (Diluted) | 7,28 | 6,74 | 0,14 | 5,71 | 5,14 |
| Gross Profit | 52,98B | 48,98B | 43,99B | 41,87B | 35,08B |
| Operating Income | 26,78B | 20,22B | 2,95B | 18,28B | 13,20B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 136,87B | 117,11B | 106,68B | 109,16B | 105,69B |
| Total Liabilities | 84,20B | 70,73B | 69,04B | 63,10B | 67,44B |
| Shareholders' Equity | 52,61B | 46,31B | 37,58B | 45,99B | 38,18B |
| Total Debt | 50,53B | 38,27B | 36,27B | 31,99B | 34,63B |
| Cash & Equivalents | 14,57B | 13,24B | 6,84B | 12,69B | 8,10B |
| Current Assets | 43,52B | 38,78B | 32,17B | 35,72B | 30,27B |
| Current Liabilities | 28,33B | 28,42B | 25,69B | 24,24B | 23,87B |